Language Selector

    IMI 2 Publishes its Strategic Research Agenda

    Published on 06 May 2014
    Author: Marlen Damjanovic, National Contact Point Health, Demographic Change & Wellbeing

    The Strategic Research Agenda (SRA) for IMI 2 provides a framework to identify the research areas that will be prioritised for funding under IMI 2.

    The SRA highlights 11 disease areas as high priorities for both the European healthcare system and the pharmaceutical industry: antimicrobial resistance, osteoarthritis, cardiovascular diseases, diabetes, neurodegenerative diseases, psychiatric diseases, respiratory diseases, autoimmune diseases, ageing-associated diseases/conditions, cancer, and orphan diseases.

    The SRA also presents a strong focus on vaccines, as well as on technologies that will enable knowledge management solutions for biomedical studies and research.

    Research conducted under IMI 2 will be tailored to deliver the tools and capabilities required to tackle these priorities to effective healthcare solutions.
     
    Further Information